國立虎尾科技大學 |

Pharmacokinetics in Drug Development = Problems and Challenges in Oncology, Volume 4 /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Pharmacokinetics in Drug Development/ edited by Peter L. Bonate, Danny R. Howard.
Reminder of title:	Problems and Challenges in Oncology, Volume 4 /
other author:	Bonate, Peter L.
Description:	XII, 330 p. 32 illus., 23 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Pharmaceutical technology. -
Online resource:	https://doi.org/10.1007/978-3-319-39053-6
ISBN:	9783319390536

Pharmacokinetics in Drug Development = Problems and Challenges in Oncology, Volume 4 /
Pharmacokinetics in Drug DevelopmentProblems and Challenges in Oncology, Volume 4 /[electronic resource] :edited by Peter L. Bonate, Danny R. Howard. - 1st ed. 2016. - XII, 330 p. 32 illus., 23 illus. in color.online resource.

Overview of Oncology Drug Development -- A Global Perspective on First-In-Man Dose Selection: Oncology and Beyond -- Controversies in Oncology: Size-Based vs. Fixed Dosing -- Clinical QTc Assessment in Oncology -- Expediting Drug Development: Breakthrough Therapy Designation -- Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors -- Combination Development -- Role of Pharmacokinetics-Pharmacodynamics in Biosimilar Assessments -- Pharmacokinetics and Pharmacogenetics of Metronomics -- Modeling Tumor Growth in Animals and Humans: an Evolutionary Approach -- Practical Considerations for Clinical Pharmacology in Oncology Drug Development: A Survey of Approvals from 2009-2015 -- New Advancements in Exposure-Response Analysis to Inform Regulatory Decision-Making .

Back cover copy In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely – to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamicconcepts for tyrosine kinases,the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist’s point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented. .

ISBN: 9783319390536

Standard No.: 10.1007/978-3-319-39053-6doiSubjects--Topical Terms:

557391
Pharmaceutical technology.

LC Class. No.: RS380

Dewey Class. No.: 615.19

Pharmacokinetics in Drug Development = Problems and Challenges in Oncology, Volume 4 /
LDR:03415nam a22004095i 4500 001 974774
003 DE-He213
005 20200629172636.0
007 cr nn 008mamaa
008 201211s2016 gw | s |||| 0|eng d
020 $a 9783319390536 $9 978-3-319-39053-6
024 7 $a 10.1007/978-3-319-39053-6 $2 doi
035 $a 978-3-319-39053-6
050 4 $a RS380
050 4 $a RS190-210
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a TDC $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a Pharmacokinetics in Drug Development $h [electronic resource] : $b Problems and Challenges in Oncology, Volume 4 / $c edited by Peter L. Bonate, Danny R. Howard.
250 $a 1st ed. 2016.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a XII, 330 p. 32 illus., 23 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Overview of Oncology Drug Development -- A Global Perspective on First-In-Man Dose Selection: Oncology and Beyond -- Controversies in Oncology: Size-Based vs. Fixed Dosing -- Clinical QTc Assessment in Oncology -- Expediting Drug Development: Breakthrough Therapy Designation -- Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors -- Combination Development -- Role of Pharmacokinetics-Pharmacodynamics in Biosimilar Assessments -- Pharmacokinetics and Pharmacogenetics of Metronomics -- Modeling Tumor Growth in Animals and Humans: an Evolutionary Approach -- Practical Considerations for Clinical Pharmacology in Oncology Drug Development: A Survey of Approvals from 2009-2015 -- New Advancements in Exposure-Response Analysis to Inform Regulatory Decision-Making .
520 $a Back cover copy In this volume, the specific challenges and problems facing the evaluation of new oncology agents are explored with regards to pharmacokinetic, pharmacodynamic modeling and clinical pharmacology development strategies. This book delivers, with an emphasis on the oncology therapeutic area, the goals set in the first three volumes: namely – to provide clinical pharmacologists practical insights for the application of pharmacology, pharmacokinetics and pharmacodynamics for new drug development strategies. Pharmacokinetic-pharmacodynamicconcepts for tyrosine kinases,the evaluation of cardiac repolarization prolongation through QTc interval effects, efficacy- and safety-response analyses to support new drug approvals, clinical and preclinical tumor growth modeling, and flat- vs weight-based dose selection are showcased from an oncology clinical pharmacologist’s point-of-view. Oncology development strategies are surveyed for new FDA-approvals to identify patterns in expectations at time of first approval. The special considerations necessary to address combination drug development, metronomics, biosimilars and breakthrough therapies are also presented. .
650 0 $a Pharmaceutical technology. $3 557391
650 0 $a Oncology . $3 1253469
650 0 $a Biomathematics. $3 527725
650 1 4 $a Pharmaceutical Sciences/Technology. $3 768561
650 2 4 $a Oncology. $3 593951
650 2 4 $a Mathematical and Computational Biology. $3 786706
700 1 $a Bonate, Peter L. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 784514
700 1 $a Howard, Danny R. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 784515
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319390512
776 0 8 $i Printed edition: $z 9783319390529
776 0 8 $i Printed edition: $z 9783319818054
856 4 0 $u https://doi.org/10.1007/978-3-319-39053-6
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)